$INTI
Inhibitor Therapeutics, Inc.

2019 Q1 Form 10-K Financial Statement

#000119312519066503 Filed on March 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 2017 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $594.8K $1.931M $370.0K
YoY Change 18.97% -33.23% -81.77%
% of Gross Profit
Research & Development $196.8K $2.634M $530.0K
YoY Change -70.8% 18.22% -27.4%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $791.6K $4.564M $910.0K
YoY Change -32.62% -10.84% -67.03%
Operating Profit -$791.6K -$4.564M
YoY Change -32.62% -10.84%
Interest Expense $5.310K $14.03K $0.00
YoY Change -21.49% -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$786.3K -$4.550M -$900.0K
YoY Change -32.8% -10.8% -67.27%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$786.3K -$4.550M -$900.0K
YoY Change -32.83% -10.8% -67.27%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$2.123K -$12.30K $0.00
COMMON SHARES
Basic Shares Outstanding 370.4M 369.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.131M $1.109M $340.0K
YoY Change -27.98% 222.2% -95.07%
Cash & Equivalents $1.131M $1.109M $344.1K
Short-Term Investments
Other Short-Term Assets $46.15K $41.30K $310.0K
YoY Change -84.62% -86.75% 0.0%
Inventory
Prepaid Expenses $46.15K $61.66K
Receivables
Other Receivables
Total Short-Term Assets $1.177M $1.150M $655.8K
YoY Change -37.22% 75.37% -90.89%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $75.67K $82.99K $112.3K
YoY Change -27.91% -26.09% -20.69%
Total Long-Term Assets $75.67K $82.99K $112.3K
YoY Change -27.91% -26.09% -20.69%
TOTAL ASSETS
Total Short-Term Assets $1.177M $1.150M $655.8K
Total Long-Term Assets $75.67K $82.99K $112.3K
Total Assets $1.253M $1.233M $768.1K
YoY Change -36.73% 60.54% -89.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $245.2K $384.8K $535.0K
YoY Change -33.76% -28.06% 79.62%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $324.8K $700.7K $601.5K
YoY Change -26.37% 16.49% 95.2%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.500M $500.0K
YoY Change
Total Long-Term Liabilities $1.500M $500.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $324.8K $700.7K $601.5K
Total Long-Term Liabilities $1.500M $500.0K $0.00
Total Liabilities $1.825M $1.201M $601.5K
YoY Change 313.64% 99.61% 95.2%
SHAREHOLDERS EQUITY
Retained Earnings -$53.82M -$48.27M
YoY Change 8.78% 11.82%
Common Stock $49.28M $48.44M
YoY Change -3.38% -3.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$572.3K $32.35K $166.6K
YoY Change
Total Liabilities & Shareholders Equity $1.253M $1.233M $768.1K
YoY Change -36.73% 60.54% -89.53%

Cashflow Statement

Concept 2019 Q1 2018 2017 Q4
OPERATING ACTIVITIES
Net Income -$786.3K -$4.550M -$900.0K
YoY Change -32.83% -10.8% -67.27%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$978.0K -$3.708M -$540.0K
YoY Change -13.58% 27.3% -55.37%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.000M 4.473M 0.000
YoY Change -57.64% -223.28% -100.0%
NET CHANGE
Cash From Operating Activities -978.0K -3.708M -540.0K
Cash From Investing Activities
Cash From Financing Activities 1.000M 4.473M 0.000
Net Change In Cash 22.01K 764.6K -540.0K
YoY Change -98.21% -111.69% -116.22%
FREE CASH FLOW
Cash From Operating Activities -$978.0K -$3.708M -$540.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
82992
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
112284
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1108713
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
344113
CY2018Q4 us-gaap Assets
Assets
1233001
CY2017Q4 us-gaap Assets
Assets
768052
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
41296
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
61655
CY2017Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
250000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
1150009
CY2017Q4 us-gaap Assets Current
AssetsCurrent
655768
CY2018Q4 us-gaap Liabilities
Liabilities
1200650
CY2017Q4 us-gaap Liabilities
Liabilities
601489
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
384829
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
534956
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
215876
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
66533
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
700650
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
601489
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
37008
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
36960
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1233001
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
768052
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49015120
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
48403523
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52980643
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48273920
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
32351
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
166563
CY2018 us-gaap Revenues
Revenues
0
CY2017 us-gaap Revenues
Revenues
0
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2633567
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2227589
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1930690
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2891442
CY2018 us-gaap Operating Expenses
OperatingExpenses
4564257
CY2017 us-gaap Operating Expenses
OperatingExpenses
5119031
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-4564257
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-5119031
CY2018 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
14027
CY2017 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
17866
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-4550230
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-5101165
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
369812939
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
366622107
CY2018 us-gaap Profit Loss
ProfitLoss
-4550230
CY2017 us-gaap Profit Loss
ProfitLoss
-5101165
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
543098
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
1865993
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-299651
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-28734
CY2018 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-785
CY2017 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
293356
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3708266
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2913082
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
12000
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
49500
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4472866
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3628227
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
764600
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6541309
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6885422
CY2017 hppi Net Settlement In Connection With Issuance Of Shares Associated With Restricted Stock Units
NetSettlementInConnectionWithIssuanceOfSharesAssociatedWithRestrictedStockUnits
3677727
CY2017 hppi Fair Value Of Shares Withheld With Net Settlement Transaction
FairValueOfSharesWithheldWithNetSettlementTransaction
3677727
CY2018 hppi Proceeds From The Sale Of Preferred Stock And Common Stock Warrants Related Party Net
ProceedsFromTheSaleOfPreferredStockAndCommonStockWarrantsRelatedPartyNet
3960866
CY2018Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2018Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
800000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-955548
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1734396
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-188002
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-176082
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
2701758
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-24357
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-369400
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1167907
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-421880
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
736325
CY2017Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
736325
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
5807112
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4759727
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
310682
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
211461
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
33943
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
9424
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2607
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6890669
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
5722762
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6890669
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5722762
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
5825
CY2018Q4 hppi Percentage Of Deferred Tax Assets Valuation Allowance
PercentageOfDeferredTaxAssetsValuationAllowance
1
CY2018Q4 hppi Net Operating Loss Amount Used To Offset Against Taxable Income
NetOperatingLossAmountUsedToOffsetAgainstTaxableIncome
35000
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3424000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.28
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
64868959
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.13
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y1M6D
CY2018Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
99945
CY2018Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
500000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
370084064
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
370084064
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
369599266
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
369599266
CY2018 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
156493
CY2018 hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-4706723
CY2017 hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-5101165
CY2018 us-gaap Stock Issued1
StockIssued1
56547
CY2018 hppi Accrued But Unpaid Dividends
AccruedButUnpaidDividends
99946
CY2018 hppi Advances Of Royalties Related Party In Financing Activities
AdvancesOfRoyaltiesRelatedPartyInFinancingActivities
-500000
CY2017Q4 hppi Percentage Of Deferred Tax Assets Valuation Allowance
PercentageOfDeferredTaxAssetsValuationAllowance
1
CY2018 us-gaap Valuation Allowance Methodologies And Assumptions
ValuationAllowanceMethodologiesAndAssumptions
In accordance with GAAP, it is required that a deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence it is more likely than not (a likelihood of more than 50 percent) that some portion or all of the deferred tax assets will not be realized.
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
32351
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.24
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
650000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.24
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6500
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
650000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.24
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
97500
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
2774000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
758000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2016000
CY2018Q4 hppi Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Exercise Price Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisePricePerShare
0.25
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2018Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1408000
CY2018Q4 hppi Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Aggregate Intrinsic Value
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsAggregateIntrinsicValue
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.00
CY2018Q2 dei Entity Public Float
EntityPublicFloat
24879000
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 hppi Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue
0
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
370446185
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
7029962
CY2017 hppi Issuance Of Common Stock Upon Exercise Of Warrants
IssuanceOfCommonStockUponExerciseOfWarrants
49500
CY2017 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-3677727
CY2017 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
1865993
CY2018 hppi Stock Issued During Period Value New Issues To Related Party
StockIssuedDuringPeriodValueNewIssuesToRelatedParty
3960866
CY2018 hppi Issuance Of Common Stock Upon Exercise Of Warrants
IssuanceOfCommonStockUponExerciseOfWarrants
12000
CY2018 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
56547
CY2018 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
543098
CY2018 us-gaap Dividends Preferred Stock
DividendsPreferredStock
156493
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018 hppi Royalty Rate On Net Sales
RoyaltyRateOnNetSales
0.09
CY2018 hppi Description Of Royalty Payment
DescriptionOfRoyaltyPayment
With respect to each Advance made by Mayne Pharma prior to the receipt of FDA approval of an NDA for SUBA-Itraconazole BCCNS, each $0.75 increment of each such Advance will be credited and set off against each $1.00 increment of Royalty owed to the Company, and with respect to each Advance made by Mayne Pharma following the receipt of FDA approval of an NDA for SUBA-Itraconazole BCCNS, each $0.85 increment of each such Advance will be credited and set off against each $1.00 increment of Royalty owed to the Company.​​​​​​​
CY2017 hppi Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
0
CY2018 hppi Fair Value Inputs Royalty Rate
FairValueInputsRoyaltyRate
0.7
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
0
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.79in; margin-top: 18pt;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Estimates </div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.79in; margin-top: 6pt;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q4 us-gaap Deferred Revenue
DeferredRevenue
0
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001042418
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018 dei Trading Symbol
TradingSymbol
HPPI
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true

Files In Submission

Name View Source Status
0001193125-19-066503-index-headers.html Edgar Link pending
0001193125-19-066503-index.html Edgar Link pending
0001193125-19-066503.txt Edgar Link pending
0001193125-19-066503-xbrl.zip Edgar Link pending
d668655d10k.htm Edgar Link pending
d668655dex105.htm Edgar Link pending
d668655dex106.htm Edgar Link pending
d668655dex107.htm Edgar Link pending
d668655dex231.htm Edgar Link pending
d668655dex311.htm Edgar Link pending
d668655dex312.htm Edgar Link pending
d668655dex321.htm Edgar Link pending
d668655dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hppi-20181231.xml Edgar Link completed
hppi-20181231.xsd Edgar Link pending
hppi-20181231_cal.xml Edgar Link unprocessable
hppi-20181231_def.xml Edgar Link unprocessable
hppi-20181231_lab.xml Edgar Link unprocessable
hppi-20181231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending